Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.[1][4] This action mimics physiological processes observed during T cell attacks against tumor cells.[4]
^Clinical trial number NCT00635596 for "Phase I Study of MT110 in Colorectal Cancer (CRC), Gastrointestinal (GI) and Lung Cancer (MT110-101)" at ClinicalTrials.gov
^Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, et al. (June 2009). "Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release". Journal of Immunotherapy. 32 (5): 452–64. doi:10.1097/CJI.0b013e3181a1c097. PMID19609237. S2CID25568468.